Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype
Aldo Caltavituro(University of Naples Federico II), Mario Giuliano(Regione Campania), Giovannella Palmieri(Regione Campania), Pietro De Placido(University of Naples Federico II), Fabio Salomone(Regione Campania), Roberto Buonaiuto(University of Naples Federico II), Marianna Tortora(Regione Campania), Margaret Ottaviano(University of Naples Federico II), Sabino De Placido, Erica Pietroluongo(University of Naples Federico II), Martina Pagliuca(Institut Gustave Roussy), Angelo Vaia(Ospedale San Carlo), Rocco Morra(Federico II University Hospital)
Cited by 3
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273